Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718716 | 0.92 | LTA4H (0.42) | HRH3EGFRLTA4H | |
| SCHEMBL4618634 | 0.89 | EGFR (0.49) | EGFRFGFR1 | |
| SCHEMBL4718778 | 0.82 | EGFR (0.47) | MKNK1EGFR | |
| SCHEMBL4717402 | 0.80 | MCHR1 (0.51) | HRH3FGFR1 | |
| SCHEMBL4871290 | 0.78 | FGFR1 (0.47) | HRH3EGFRFGFR1 | |
| SCHEMBL4716494 | 0.78 | CCR3 (0.46) | HRH3 | |
| SCHEMBL4717516 | 0.77 | MCHR1 (0.47) | HRH3HRH4LTA4H | |
| SCHEMBL3572561 | 0.77 | EGFR (0.38) | EGFRFGFR1 | |
| SCHEMBL13499918 | 0.75 | EGFR (0.43) | EGFRFGFR1 | |
| SCHEMBL4718602 | 0.74 | ALDH1A1 (0.46) | FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1846399-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082371-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | MKNK1 2204/4885HRH3 191/4885EGFR 334/4885 |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | TIE1, TEK, KDR | MKNK1 2620/4885HRH3 351/4885EGFR 414/4885 |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | MKNK1 2209/4885HRH3 511/4885EGFR 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.